ReviewFrontiers in immunology2022

Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma.

Endeshaw Chekol Abebe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.